Published in Pathobiology on April 04, 2012
Aspirin on CTCs of Advanced Breast and Colorectal Cancer (ACABC) | NCT02602938
Crossing the endothelial barrier during metastasis. Nat Rev Cancer (2013) 2.00
EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget (2015) 1.92
Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis (2013) 1.20
Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer (2014) 1.13
Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One (2015) 1.08
Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med (2012) 1.04
Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One (2012) 1.02
Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation. Evid Based Complement Alternat Med (2013) 0.95
The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol (2014) 0.94
P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an "Intermediate/Metastable" EMT State. Front Oncol (2015) 0.91
CD44 is associated with the aggressive phenotype of nasopharyngeal carcinoma through redox regulation. Int J Mol Sci (2013) 0.86
Cell adhesion molecules in metastatic neuroblastoma models. Clin Exp Metastasis (2014) 0.84
Emerging molecular basis of hematogenous metastasis in gastric cancer. World J Gastroenterol (2016) 0.84
Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. PLoS One (2014) 0.84
Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers (Basel) (2013) 0.83
Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. Am J Transl Res (2015) 0.83
Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget (2016) 0.82
Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines. Cancer Sci (2014) 0.81
Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma. J Cancer Res Clin Oncol (2015) 0.81
SELEX aptamer used as a probe to detect circulating tumor cells in peripheral blood of pancreatic cancer patients. PLoS One (2015) 0.80
Contactin 1: A potential therapeutic target and biomarker in gastric cancer. World J Gastroenterol (2015) 0.80
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo. Oncol Lett (2014) 0.79
May CTC technologies promote better cancer management? EPMA J (2015) 0.79
STAT3 regulates hypoxia-induced epithelial mesenchymal transition in oesophageal squamous cell cancer. Oncol Rep (2016) 0.78
Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation. Am J Transl Res (2014) 0.78
Cellular Plasticity in Prostate Cancer Bone Metastasis. Prostate Cancer (2015) 0.78
The Challenges of Detecting Circulating Tumor Cells in Sarcoma. Front Oncol (2016) 0.77
N-nitroso-N-ethylurea activates DNA damage surveillance pathways and induces transformation in mammalian cells. BMC Cancer (2014) 0.77
Prognostic significance of circulating tumor cells in esophageal carcinoma: a meta-analysis. Onco Targets Ther (2016) 0.77
Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells. Oncol Lett (2015) 0.76
Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation. Oncotarget (2016) 0.76
High FMNL3 expression promotes nasopharyngeal carcinoma cell metastasis: role in TGF-β1-induced epithelia-to-mesenchymal transition. Sci Rep (2017) 0.75
Circulating Tumor Cells: From Theory to Nanotechnology-Based Detection. Front Pharmacol (2017) 0.75
Cancer stem cells in prostate cancer. Transl Androl Urol (2013) 0.75
Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer. Oncol Lett (2016) 0.75
Long-term prognostic impact of circulating tumour cells in gastric cancer patients. World J Gastroenterol (2016) 0.75
Interrelationships of circulating tumor cells with metastasis and thrombosis: role of microRNAs. Curr Pharm Des (2014) 0.75
EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect. Oncotarget (2016) 0.75
Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int J Clin Exp Pathol (2015) 0.75
Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy. J Biol Chem (2015) 0.75
Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains. PLoS One (2013) 0.75
CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol (2012) 1.06
Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med (2012) 1.04
Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res (2012) 0.88
Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers (Basel) (2013) 0.83
Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin Biochem (2010) 0.82
Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. Oncologist (2012) 0.81
[Housekeeping genes as a reference in quantitative real-time RT-PCR]. Postepy Hig Med Dosw (Online) (2007) 0.81
Deregulation of RAD21 and RUNX1 expression in endometrial cancer. Oncol Lett (2012) 0.80
HER2-positive endometrial cancer subtype carries poor prognosis. Clin Transl Sci (2014) 0.77
Epithelial-mesenchymal transition and cancer stem cells in endometrial cancer. Anticancer Res (2013) 0.77
Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients. PLoS One (2013) 0.75